Saluda Medical receives $10 million in Series B financing

Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain one step closer to reality.

The company, a successful spin-out from NICTA, Australia's Information Communications and Technology (ICT) Research Centre of Excellence, is developing world-first neuromodulation technologies that will improve the treatment of chronic pain, Parkinson's disease, epilepsy and other debilitating disorders.

Neuromodulation generates therapeutic nerve activity through the delivery of electrical stimulation to targeted sites in the body. Saluda is developing a neuromodulation device that measures nerve signals and adjusts stimulation in real time to achieve optimal outcomes for patients. With 1.5 billion people suffering from chronic pain worldwide, Saluda's research will bring an increased quality of life to many across the globe.

New investor Biosciences Managers led the funding round, in which existing investors also participated. Saluda intends to use the funds to conduct chronic clinical trials and support commercialization plans for its Evoke™ spinal cord stimulation system to treat chronic pain of the trunk and limbs.

Saluda CEO John Parker commented: "We are delighted to welcome Biosciences Managers as a key shareholder. Their knowledge and experience in the world of medical devices will complement our extraordinary group of existing investors to support Saluda through its next phases of evolution."

"With the new funding support we are able to open the next chapter of research into chronic pain, bringing us closer to commercializing a revolutionary treatment that promises to help many people," continued Dr. Parker.

Biosciences Managers views Saluda's neuromodulation device as a potential breakthrough technology in treating pain and other disorders. The organization places a high value on the technology, which is close to commercialization with potentially very large markets.

Prior to its spin-out Saluda received four years of research funding from NICTA. The company has also worked in close collaboration with the Pain Management Research Institute at the Royal North Shore Hospital in Sydney, and received a grant from the government of New South Wales Medical Device Fund.

Note: Caution - Investigational Device, Limited by United States Law to Investigational Use.

Source:

Saluda Medical

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Endogenous retrovirus type W found to be a major contributor to nerve damage in MS